No Data
No Data
OncoTherapy Science 1H Loss Y545.00M Vs Loss Y710.00M
OncoTherapy Science: Confirmation letter
OncoTherapy Science: Interim report - 24th term (2024/04/01 - 2025/03/31)
SoftBank, upward revision on 25/3, operating profit 950 billion yen ← 900 billion yen
SoftBank <9434> announced a revision to its financial estimates for the fiscal year ending in March 2025. The revenue has been upwardly revised from 6.2 trillion yen to 6.35 trillion yen, and the operating profit from 900 billion yen to 950 billion yen. The strong performance of its subsidiary, the leading smart phone payment provider PayPay, as well as the recovery of its mobile business, have contributed to this. [Positive evaluation] <9735> secom co midterm | <4521> Kaken Pharmaceutical midterm <7733> Olympus midterm | <8362> Fukui Bank revision <9005> Tokyu midterm | <4
OncoTherapy Science: Summary of financial results for the 2nd quarter (interim period) of the fiscal year ending 2025/3 [Japanese GAAP] (consolidated)
The TSE Growth Market Index rebounded, with funds heading to the main market.
Tokyo Stock Exchange Growth Market Index 830.58 +3.23 / Volume 0.1 billion 40.65 million shares / Trading value 97.5 billion yen. Tokyo Stock Exchange Growth Market 250 Index 650.01 +2.81 / Volume 80.68 million shares / Trading value 79.4 billion yen. In today's growth market, both the Tokyo Stock Exchange Growth Market Index and the Tokyo Stock Exchange Growth Market 250 Index rebounded. The number of advancing stocks is 266, declining stocks is 276, unchanged is 42. In the U.S. market on the 4th, the Dow Jones Industrial Average rose by 341.16 points to 42,352.75 points.
No Data
No Data